Строение и функции костной ткани в норме и при патологии. Сообщение II
Аннотация
Во второй части обзора рассмотрены вопросы функции остеоцитов, покровных клеток и остеокластов, а также их взаимодействия. Обсуждаются процессы моделирования и ремоделирования кости.
Об авторах
А. В. Смирнов
Первый Санкт-Петербургский государственный медицинский университет
Россия
Россия
А. Ш. Румянцев
Первый Санкт-Петербургский государственный медицинский университет
Россия
Россия
Список литературы
1. Manolagas S.C. Birth And Death Of Bone Cells: basic Regulatory Mechanisms And Implications For The Pathogenesis And Treatment Of Osteoporosis. Endocr Rev. 2000; 21(2): 115-137
2. Plotkin L.I., Manolagas S.C., Bellido T. Transduction of cell survival signals by connexin-43 hemichannels. J Biol Chem. 2002; 277(10): 8648-8657
3. Bonewald l.F Establishment and characterization of an osteo-cyte- like cell line, MLO-Y4. J Bone Miner Metab. 1999; 17(1): 61-65
4. Knothe Tate M.L., Adamson J.R., Tami A.E., Bauer T.W. The osteocyte. Int J Biochem Cell Biol. 2004; 36(1): 1-8
5. Bonewald l.F. Osteocytes: a proposed multifunctional bone cell. J Musculoskelet Neuronal Interact. 2002; 2(3): 239-241
6. Winkler D.G., Sutherland M.K., Geoghegan J.C. et al. Osteocyte control of bone formation via sclerostin, a novel bmp antagonist. EMBO J. 2003; 22(23): 6267-6276
7. ten Dijke P., Krause C., de Gorter D.J. et al. Osteocyte- derived sclerostin inhibits bone formation: its role in bone morphogenetic protein and Wnt signaling. J Bone Joint Surg Am. 2008; 90 Suppl 1: 31-35
8. Ubaidus S., Li M., Sultana S. et al. FGF23 is mainly synthesized by osteocytes in the regularly distributed osteocytic lacunar canalicular system established after physiological bone remodeling. J Electron Microsc (Tokyo). 2009; 58(6): 381-392
9. Clarke B. Normal bone anatomy and physiology. Clin J Am Soc Nephrol. 2008;3 Suppl 3: S131-139
10. Seeman E., Delmas p.D. Bone guality - the material and structural basis of bone strength and fragility. N Engl J Med. 2006; 354(21): 2250-2261
11. Robinson J.A., Chatterjee- Kishore M., Yaworsky P.J. et al. Wnt/beta- catenin signaling is a normal physiological response to mechanical loading in bone. J Biol Chem. 2006; 281(42): 3172031728
12. Fritton S.P., Weinbaum S. Fluid and solute transport in bone: flow- induced mechanotransduction. Annu Rev Fluid Mech. 2009; 41: 347-374
13. Xing L., Boyce B.F. Reculation of apoptosis in osteoclasts and osteoblastic cells. Biochem Biophys Res Commun. 2005; 328(3): 709-720
14. Plotkin L.I., Aguirre J.L., Kousteni S. et al. Bisphosphonates and estrogens inhibit osteocyte apoptosis via distinct molecular mechanisms downstream of extracellular signal- regulated kinase activation. J Biol Chem. 2005; 280(8): 7317-7325
15. Dierkes C., Kreisel M., Schulz A. et al. Catabolic properties of microdissected human endosteal bone lining cells. Calcif Tissue Int. 2009; 84(2): 146-155
16. Yavropoulou M.P., Yovos J.G. Osteoclastogenesis - current knowledge and future perspectives. J Musculoskelet Neuronal Interact. 2008; 8(3): 204-216
17. Felix R., Halasy-Nagy J., Wetterwald A. et al. Synthesis of membrane- and matrix- bound colony- stimulating factor-1 by cultured osteoblasts. J Cell Physiol. 1996; 166(2): 311-322
18. Dai X.M., Ryan G.R., Hapel A.J. et al. Targeted disruption of the mouse colony- stimulating factor 1 receptor gene results in osteopetrosis, mononuclear phagocyte deficiency, increased primitive progenitor cell freguencies, and reproductive defects. Blood. 2002; 99(1): 111-120
19. Tondravi M.M., Mckercher S.R., Anderson K. et al. Osteopetrosis in mice lacking haematopoietic transcription factor PU.1. Nature. 1997; 386(6620): 81-84
20. Sharma S.M., Bronisz A., Hu R. et al. MITF and PU.1 recruit p38 MAPK and NFATc1 to target genes during osteoclast differentiation. J Biol Chem. 2007; 282(21): 15921-1599
21. Yamashita T. ,Yao Z., Zhang Q. et al. NF-kappa B p50 and p52 regulate receptor activator of NF-kappaB ligand (RANKL) and tumor necrosis factor- induced osteoclast precursor differentiation by activating c-Fos and NFATc1. J Biol Chem. 2007; 282(25): 18245-18253
22. Kim H., Choi H.K., Shin J.H. et al. Selective inhibition of RANK blocks osteoclast maturation and function and prevents bone loss in mice. J Clin Invest. 2009; 199(4): 813-825
23. Roodman G.D. pathogenesis of myeloma bone disease. J Cell Biochem. 2010; 109(2): 283-291
24. Gluliani N., Colla S., Rizzoli V. Update on the pathogenesis of osteolysis in multiple myeloma patients. Acta Biomed. 2004; 75(3): 143-152
25. Li J., Sarosi I., Yan X.Q. et al. RANK is the intrinsic hematopoietic cell surface receptor that controls osteoclastogenesis and regulation of bone mass and calcium metabolism. Proc Natl Acad Sci USA. 2000; 97(4): 1566-1571
26. Charopoulos I., Orme S., Giannoudis P.V. The role and efficacy of denosumab in the treatment of osteoporosis: an update. expert opin drug Saf. 2011; 10(2):205-17
27. Gillespie M.T. impact of cytokines and t lymphocytes upon osteoclast differentiation and function. Arthritis Res Ther. 2007; 9(2): 103
28. Tolar J., Teitelbaum S.L., Orchard P.J. Osteopetrosis. N Engl J Med. 2004; 351 (27): 2839-2849
29. Teitelbaum S.L. Osteoclasts: what do they do and how do they do it? Am J Pathol. 2007; 170(2): 427-435
30. Ross F.P., Teitelbaum S.L. Alphavbeta3 and macrophage colony- stimulating factor: partners in osteoclast biology. Immunol Rev. 2005; 208: 88-105
31. Blair H.C., Zaidi M., Schlesinger P.H. Mechanisms balancing skeletal matrix synthesis and degradation. Biochem J. 2002; 364(Pt 2): 329-341
32. Burstone M.S. Histochemical demonstration of acid phosphatase activity in osteoclasts. J Histochem Cytochem. 1959; 7(1): 39-41
33. Seibel M.J. Biochemical markers of bone turnover: Part I: Biochemistry and variability. Clin Biochem Rev. 2005; 26(4): 97-122
34. Ek-Rylander B., Flores M., Wendel M. et al. Dephosphorylation of osteopontin and bone sialoprotein by osteoclastic tartrate-resistant acid phosphatese. modulation of osteoclast adhesion in vitro. J Biol Chem. 1994; 269(21): 14853-14856
35. Murphy M.G., Cerchio K., Stoch S.A. et al. Effect of L-000845704, an alpha vbeta3 integrin antagonist, on markers of bone turnover and bone mineral density in postmenopausal osteoporotic women. J Clin Endocrinol Metab. 2005; 90(4): 2022-2028
36. Pérez-Castrillôn J.L., Pinacho F., De Luis D. et al. Odanacatib, a new drug for the treatment of osteoporosis: review of the results in postmenopausal women. J osteoporos. 2010; 2010.pii: 401581
37. Денисов-Никольский Ю.И., Докторов А.А., Матвейчук И.В. Структура и функция костной ткани в норме: в кн.: Руководство по остеопорозу. Под ред. Л.И.Беневоленской.-М.: БИНОМ. Лаборатория знаний. 2003; 524 с- гл. 2, с.56-76 [Denisov-Nikol'skii' Iu.I., Doktorov A.A., Matvei'chuk I.V. Struktura i funktciia kostnoi' tkani v norme: v kn.: Rukovodstvo po osteoporozu. Pod red. L.I.Benevolenskoi'.- M.: BINOM. LABORATORIIAZNANII'. 2003; 524 S- GL. 2, S.56-76]
38. Hadjidakis D.J., Androulakis I.I. Bone remodeling. Ann N Y Acad Sci. 2006; 1092: 385-396
39. Беневоленская Л.И., Насонов Е.А. Патогенез остеопороза: в кн.: Руководство по остеопорозу. Под ред. Л.И.Беневоленской.- М.: БИНОМ. Лаборатория знаний. 2003; - 524 с- гл. 3, с.77-104 [Benevolenskaia L.I., Nasonov E.A. patogenez osteoporoza: V kn.: Rukovodstvo po osteoporozu. Pod red. L.I.Benevolenskoi'.- M.: BINOM. LABORATORIIA ZNANII'. 2003; - 524 S- GL. 3, S.77-104]
40. Котельников Г.П., Булгакова С.В. Остеопороз: руководство. М.: ГЭОТАР- Медиа. 2010; 512 с [Kotel'nikov G.P., Bulgakova S.V. Osteoporoz: rukovodstvo. M.: GEOTAR- MEDIA. 2010; 512 S]
41. Hauge E.M., Qvesel D., Eriksen E.F. et al. Cancellous bone remodeling occurs in specialized compartments lined by cells expressing osteoblastic markers. J Bone Miner Res. 2001; 16(9): 1575-1582
42. Eriksen E.F., Eghbali- Fatourechi G.Z., Khosla S. Remodeling and vascular spaces in bone. J Bone Miner Res. 2007; 22(1): 1-6
43. Khosla S., Westendorf J.J., Oursler M.J. Building bone to reverse osteoporosis and repair fractures. J Clin Invest. 2008; 118(2): 421-428
44. Mohan S., Baylink D.J. Insulin- like growth factor system components and the coupling of bone formation to resorption. Horm Res. 1996; 45 Suppl 1: 59-62
45. Bonewald L.F., Mundy G.R. Role of transforming growth factor- beta in bone remodeling. Clin Orthop Relat Res. 1990; (250): 261-276
46. Zhao C., Irie N., Takada Y. et al. Bidirectional Ephrin B2-Eph B4 signaling controls bone homeostasis. Cell Metab. 2006; 4(2): 111-121
47. Matsuo K., Irie N. Osteoclast- osteoblast communication. Arch Biochem Biophys. 2008; 473(2): 201-209
48. Ryu J., Kim H.J., Chang E.J. et al. Sphingosine 1-phosphate as a regulator of osteoclast differentiation and osteoclast- osteoblast coupling. Embo J. 2006; 25(24): 5840-5851
49. Irie N., Takada Y., Watanabe Y. et al. Bidirectional signaling through ephrin A2- Eph A2 enhances osteoclastogenesis and suppresses osteoblastogenesis. J Biol Chem. 2009; 284(21): 14637-14644
50. Martin T.J., Allan E.H., Ho P.W. et al. Communication between Ephrin B2 and Eph B4 within the osteoblast lineage. Adv Exp Med Biol. 2010; 658: 51-60
51. Martin T.J., Gooi J.H., Sims N.F. Molecular mechanisms in coupling of bone formation to resorption. Crit Rev Eukaryot Gene Expr. 2009; 19(1): 73-88
Для цитирования:
Смирнов А.В., Румянцев А.Ш. Строение и функции костной ткани в норме и при патологии. Сообщение II. Нефрология. 2015;19(1):8-17.
For citation:
Smirnov A.V., Rumyantsev A.S. Bone tissue function and structure under normal and pathological condition. Message ". Nephrology (Saint-Petersburg). 2015;19(1):8-17. (In Russ.)
Просмотров: 332
Послать статью по эл. почте 